As Vice President of Business Development, Colin Lin will be responsible for leading the overall BD, public relations, and investor relations departments in Yoltech, he will bring high-quality R&D and commercial resources and investment opportunities to the company through various of partnership including out-licensing and financing, to empower pipeline competence and promote business growth.
Colin started career from Novartis internship and then got MT offer from Johnson & Johnson Medical. Led multiple healthcare licensing, strategy, and equity projects in Eisai. Acted as brand owner of company’s best selling product in Boehringer Ingelheim. As head of BD at Alphamab, led 10+ deals, including inlicensing, global out-licensing, and multi-spectrum deals (total deal size nearly $1.0 Bn).
Colin has 15 years of pharmaceutical industry experience in business development, strategy & alliance management, etc. Led to complete a number of licensing deals, strategic cooperation and equity investment projects, owned a wealth of experience across all parts of business development value chain, familiar with various of disease fields. He is PhD candidate in montpellieruniversity, received a master's degree in biomedicine from the China Academy of Science and a MBA degree in CEIBS.